4DIEKEMA DJ, PFALLER MA, SCHMITZ FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997 - 1999[J]. Clin Infect Dis, 2001,32 Suppl 2: S114- S132. 被引量：1
5ALLEN NE, NICAS TI. Mechanism of action of oritavancin and related glycopeptide antibiotics[J]. FEMS Microbiol Rev, 2003, 26(5):511 - 532. 被引量：1
6PATEL R, ROUSE MS, PIPER KE, et al. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin- resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae [J]. Diagn Microbiol Infect Dis, 1998, 30(2): 89 - 92. 被引量：1
7van BAMBEKE F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy[J]. Curr Opin Investig Drugs, 2006, 7 (8) : 740-749. 被引量：1
8CITRON DM, KWOK YY, APPLEMAN MD, In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens , Propionlbacterium aches , and anaerobic Gram-positive cocci[J]. Anaerobe, 2005, 11 (1-2) : 93 - 95. 被引量：1
9COREY GR, STRYJEWSKI ME, O'RIORDAN WD, et al. ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections [J]. Clin Microb Infect, 2007, 29 Suppl 2: S216- S217. 被引量：1
10COREY GR, STRYJEWSKI ME, FOWLER VG, et al. ATLAS 2: a double-blind, randomised, active controlled, multinational Phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections[J]. Clin Microb Infect, 2007, 29 Suppl 2: S217. 被引量：1
